ClinicalTrials.gg
CompletedNCT02517866Updated Mar 1, 2019Results posted

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

A Phase 4 interventional study of Azilsartan Medoxomil in Essential Hypertension and Type 2 Diabetes Mellitus, sponsored by Takeda. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-01.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
380
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing azilsartan medoxomil in Essential Hypertension — none open to participants now, none under way, none of them phase 3. azilsartan medoxomil · Essential Hypertension.

Enrollment
11th of 11
380 · median 837
Started
2015
with 1 other
Phase 4
Only one
of the 11
Registered
11th of 11
by date
Lead sponsor
11 of 11
Takeda

Among the 11 studies testing azilsartan medoxomil in Essential Hypertension, this one is the 11th largest by enrollment, is one of 2 that started in 2015, is the only one in phase 4, and was the 11th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

None of the 11 studies testing azilsartan medoxomil in Essential Hypertension is open now. The open studies under Essential Hypertension, anywhere →

About azilsartan medoxomil

azilsartan medoxomil: first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing azilsartan medoxomil in Essential Hypertension as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.

Read the detailed description

The drug being tested in this study is called azilsartan medoxomil. Azilsartan medoxomil is being tested to treat people who have essential hypertension and type 2 diabetes mellitus (T2DM). This study will look at the blood pressure of people who take azilsartan medoxomil in addition to standard care for T2DM.

The study will enroll approximately 380 patients. All participants will receive azilsartan medoxomil 40 mg tablets to be administered orally, once a day, for 12 weeks. If a participant's blood pressure (BP) has not reached BP goal of \<140/85 mmHg at week 6, azilsartan medoxomil dose will be up-titrated to 80 mg daily.

All participants will be asked to take one tablet at the same time each day throughout the study.

This multi-center trial will be conducted in Asia. The overall time to participate in this study is 14 weeks. Participants will make multiple visits to the clinic, and will be contacted by 14 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Essential Hypertension
  • Type 2 Diabetes Mellitus

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has type 2 diabetes mellitus (T2DM) with essential hypertension.
  4. T2DM participants are either treated by stable life style intervention or by oral antidiabetic drugs (OADs) that are stable, including no dose adjustment within 12 weeks before baseline.
  5. Is male or female and aged 18 to 75 years, inclusive.
  6. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg to \<180 mmHg, or diastolic blood pressure ≥85 mmHg and \<110 mmHg at screening and baseline.
  7. Has screening glycosylated () \<9.5%.
  8. Female participants must be either of non-, ie, surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year after the last menstrual period; or, if of childbearing potential and participant is sexually active with a nonsterilized male partner, must agree to use routinely adequate from signing of informed consent throughout the duration of study.

Exclusion criteria

Exclusion Criteria:

  1. Has systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg despite concurrent treatment with three antihypertensive medications from different classes at adequate doses including a diuretic.
  2. Has type 1 or poorly controlled type 2 diabetes mellitus, defined as ≥9.5% at screening.
  3. Is treated with OADs has not been on stable treatment including no dose change of their OADs for at least 12 weeks prior to baseline.
  4. Has been previously treated with azilsartan medoxomil (AZM) or azilsartan.
  5. Has secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  6. Has congestive heart failure ( class III or IV), cardiac arrhythmias (as determined by the investigator's clinical judgment on a participant-by-participant basis), severe obstructive coronary artery disease.
  7. Has participated in a clinical trial including interventional and observational studies, or received any compound currently or 30 days prior to screening.
  8. Has severe renal impairment (based on estimated [GFR] \<30 mL/min/1.73m\^2) at Screening.
  9. Has hyperkalemia defined as serum potassium >5.0 mEq/L.
  10. Has an (ALT) level of greater than 2.5 times the , active liver disease, or jaundice at screening.
  11. Has any clinically relevant disease (eg , neurological, hepatic abnormalities) and/or significant abnormal laboratory findings (past or present), which, in the opinion of the investigator, may put the participant at risk because of participation in the study.
  12. Is taking prohibited medications including lithium and aliskiren (refer to Edarbi® product insert).
  13. Has known to any or angiotensin converting enzyme inhibitor (ACEIs)/ angiotensin receptor blockers (ARBs).
  14. Has prior angioedema due to an ACE inhibitor or ARB.
  15. Breast feeding or pregnant women or women who are intending to become pregnant before, during or within 1 month after participating in the study; or intending to donate ova during such time period, or refusal to submit to a urine test to rule out pregnancy prior to enrolment and at end of study.
  16. Have a history of alcohol abuse, drug abuse or illegal drug addiction within the 6 months prior to signing the .
  17. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    Azilsartan medoxomil

    Azilsartan medoxomil 40 mg, tablets, orally, once, daily, for 12 weeks. Azilsartan medoxomil dose may be increased to 80 mg once daily if blood pressure has not reach BP goal of \<140/85 mmHg at Week 6.

    Drug: Azilsartan Medoxomil

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg

    Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Up to Week 12

  2. Percentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg

    At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Weeks 6 and 12

  3. Percentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Weeks 6 and 12

  4. Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg

    At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Weeks 6 and 12

  5. Percentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg

    Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Up to Week 12

  6. Percentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Weeks 6 and 12

  7. Percentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Weeks 6 and 12

  8. Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Weeks 6 and 12

  9. Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  10. Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  11. Percentage of Participants With DBP <90 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  12. Percentage of Participants With BP <130/80 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  13. Percentage of Participants With SBP <130 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  14. Percentage of Participants With DBP <80 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  15. Percentage of Participants With BP <140/90 mmHg at Week 12

    Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

    Time frame: Week 12

  16. Change From Baseline in Trough Sitting SBP at Week 12

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  17. Change From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  18. Change From Baseline in DBP at Week 12

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

  19. Change From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants

    At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

    Time frame: Baseline and Week 12

07

Results

Posted Mar 1, 2019

Participant flow

Participants took part in the study at 34 investigative sites in Hong Kong, Taiwan and Thailand from 13 July 2015 to 25 November 2016.

Participant flow — Overall Study
MilestoneAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Started289901
Completed269841
Not completed2060
Withdrew: Pretreatment event/adverse event920
Withdrew: Significant protocol deviation410
Withdrew: Lost to follow-up100
Withdrew: Voluntary withdrawal220
Withdrew: Investigator decision210
Withdrew: Reason not specified200

Outcome measures

PrimaryPercentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)
Percentage of Participants With Blood Pressure (BP) <140/85 mmHg (Systolic BP <140 mmHg and Diastolic BP <85 mmHg) by Clinic-Measured Sitting BP at Week 1259.8 (43.40 to 63.08)65.9 (44.07 to 75.70)
SecondaryPercentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg

Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg
percentage of participantsAzilsartan Medoxomil (Treatment-Naïve)
Percentage of "Treatment-Naïve" Participants Reaching BP <140/85 mmHg0.0 (NA to NA)
SecondaryPercentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg

At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Treated With Calcium Channel Blocker (CCB) Before Baseline Reaching BP<140/85 mmHg
percentage of participantsAzilsartan Medoxomil
Week 657.8 (45.36 to 71.12)
Week 1252.3 (39.75 to 65.08)
SecondaryPercentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Treated With Angiotensin Converting Enzyme (ACE) Inhibitors or Other Angiotensin Receptor Blockers (ARBs) Before Baseline Reaching BP <140/85 mmHg
percentage of participantsAzilsartan Medoxomil
Week 663.7 (44.83 to 68.92)
Week 1263.7 (44.73 to 69.01)
SecondaryPercentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg

At each visit three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <140/85 mmHg
percentage of participantsAzilsartan Medoxomil
Week 679.3 (45.97 to 89.46)
Week 1286.2 (43.81 to 97.18)
SecondaryPercentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg

Treatment-naïve participants are defined as participants who have not received anti-hypertensive treatment for at least four weeks prior to screening. At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg
percentage of participantsAzilsartan Medoxomil (Treatment-Naïve)
Percentage of "Treatment-Naïve" Participants Reaching BP <130/80 mmHg0.0 (NA to NA)
SecondaryPercentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Treated With CCB Before Baseline Reaching BP <130/80 mmHg
percentage of participantsAzilsartan Medoxomil
Week 626.6 (14.73 to 36.50)
Week 1227.5 (15.73 to 37.10)
SecondaryPercentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Treated With ACE Inhibitors or Other ARBs Before Baseline Reaching BP <130/80 mmHg
percentage of participantsAzilsartan Medoxomil
Week 631.1 (10.05 to 33.20)
Week 1235.2 (12.18 to 37.37)
SecondaryPercentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Weeks 6 and 12
Reported as:
Number · percentage of participants
Percentage of Participants Treated With Thiazides Before Baseline Reaching BP <130/80 mmHg
percentage of participantsAzilsartan Medoxomil
Week 641.4 (21.13 to 65.05)
Week 1251.7 (29.12 to 73.67)
SecondaryPercentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With Systolic Blood Pressure (SBP) <140 mmHg at Week 1268.8 (57.57 to 75.78)70.6 (52.49 to 83.94)0.0 (NA to NA)
SecondaryPercentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With Diastolic Blood Pressure (DBP) <85 mmHg at Week 1274.6 (64.86 to 81.66)81.2 (67.40 to 91.05)0.0 (NA to NA)
SecondaryPercentage of Participants With DBP <90 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With DBP <90 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With DBP <90 mmHg at Week 1287.3 (85.11 to 95.34)87.1 (79.97 to 96.46)0.0 (NA to NA)
SecondaryPercentage of Participants With BP <130/80 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With BP <130/80 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With BP <130/80 mmHg at Week 1233.7 (17.01 to 37.26)40.0 (18.66 to 48.66)0.0 (NA to NA)
SecondaryPercentage of Participants With SBP <130 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With SBP <130 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With SBP <130 mmHg at Week 1241.3 (22.25 to 43.20)43.5 (20.17 to 50.31)0.0 (NA to NA)
SecondaryPercentage of Participants With DBP <80 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With DBP <80 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With DBP <80 mmHg at Week 1257.6 (36.82 to 59.95)65.9 (41.33 to 75.07)0.0 (NA to NA)
SecondaryPercentage of Participants With BP <140/90 mmHg at Week 12

Three serial BP measurements were determined while the participant was seated, with a sphygmomanometer.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With BP <140/90 mmHg at Week 12
percentage of participantsAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)Azilsartan Medoxomil (Treatment-Naïve)
Percentage of Participants With BP <140/90 mmHg at Week 1265.9 (52.51 to 71.04)68.2 (48.42 to 79.92)0.0 (NA to NA)
SecondaryChange From Baseline in Trough Sitting SBP at Week 12

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in Trough Sitting SBP at Week 12
mmHgAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)
Change From Baseline in Trough Sitting SBP at Week 12-14.1 ± 1.39-13.3 ± 2.12
SecondaryChange From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, baseline hypertension therapy (BHT) and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmHg
Change From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants
mmHgAzilsartan Medoxomil (Treatment-Naïve)
Change From Baseline in Trough Sitting SBP at Week 12 in "Treatment-Naïve" Participants-7 ± NA
SecondaryChange From Baseline in DBP at Week 12

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mmHg
Change From Baseline in DBP at Week 12
mmHgAzilsartan Medoxomil (Switched)Azilsartan Medoxomil (Add-On)
Change From Baseline in DBP at Week 12-4.9 ± 0.76-5.7 ± 1.16
SecondaryChange From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants

At each visit 3 serial BP measurements were determined while the participant was seated, with a sphygmomanometer. Change from Baseline was estimated using an ANCOVA model with fixed effects, country, BHT and baseline SBP (or DBP) included as a covariate. A negative change from baseline indicates improvement.

Time frame:
Baseline and Week 12
Reported as:
Mean · mmHg
Change From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants
mmHgAzilsartan Medoxomil (Treatment-Naïve)
Change From Baseline in DBP at Week 12 in "Treatment-Naïve" Participants20 ± NA

Adverse events

Collected over From first dose of study drug up to 14 days after the date of the last dose of study drug (up to 14 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Before Week 6 Azilsartan Medoxomil 40 mg—4/380 (1.1%)0/380 (0%)
After Week 6 Azilsartan Medoxomil 40 mg—3/258 (1.2%)0/258 (0%)
After Week 6 Azilsartan Medoxomil 80 mg—1/97 (1%)0/97 (0%)
Most frequent serious events
Most frequent serious events
EventBefore Week 6 Azilsartan Medoxomil 40 mgAfter Week 6 Azilsartan Medoxomil 40 mgAfter Week 6 Azilsartan Medoxomil 80 mg
PneumoniaInfections and infestations0/3800/2581/97
SepsisInfections and infestations0/3800/2581/97
Acute kidney injuryRenal and urinary disorders1/3801/2581/97
Acute myocardial infarctionCardiac disorders0/3801/2580/97
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3801/2580/97
Cardiac failureCardiac disorders1/3800/2580/97
Respiratory failureRespiratory, thoracic and mediastinal disorders1/3800/2580/97
HypotensionVascular disorders1/3800/2580/97

Baseline characteristics

Safety analysis set included all participants who took at least 1 dose of azilsartan medoxomil.

Age, Continuous
Age, Continuous(years)Azilsartan Medoxomil
Mean61.6 ± 9.77
Age, Customized
Age, Customized(Participants)Azilsartan Medoxomil
< 65 years old221
>=65 to <75 years old159
Sex: Female, Male
Sex: Female, Male(Participants)Azilsartan Medoxomil
Female197
Male183
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Azilsartan Medoxomil
Asian380
Region of Enrollment
Region of Enrollment(Participants)Azilsartan Medoxomil
Taiwan, Province Of China139
Thailand219
Hong Kong22
Height
Height(cm)Azilsartan Medoxomil
Mean161.1 ± 9.57
Weight
Weight(kg)Azilsartan Medoxomil
Mean72.04 ± 15.072
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Azilsartan Medoxomil
Mean27.64 ± 4.354

3 further baseline measures are reported on the registry.

08

Study locations

12 sites
  • Hong Kong, Hong Kong, China
  • Changhua County, Taiwan
  • Kaohsiung City, Taiwan
  • Kaohsiung, Taiwan
  • Taichung, Taiwan
  • Tainan City, Taiwan
  • Taipei, Taiwan
  • Taoyuan County, Taiwan
  • Bangkok, Thailand
  • Chiang Mai, Thailand
  • Khon Kaen, Thailand
  • Pathumthani, Thailand
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2015 to primary completion in Nov 2016, 16 months.

Results were first posted in Mar 2019, 2 years 3 months after primary completion.

Of 22 phase 4 interventional studies under Essential Hypertension, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 36. This study's 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2015
First posted
Aug 7, 2015
StartActual
Jul 13, 2015
Primary completionActual
Nov 15, 2016
CompletionActual
Nov 25, 2016
Results first posted
Mar 1, 2019
Last update
Mar 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02517866
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Aug 7, 2015
Start date
Jul 13, 2015
Primary completion
Nov 15, 2016
Completion
Nov 25, 2016
Results posted
Mar 1, 2019
Last update
Mar 1, 2019

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azilsartan medoxomil

Start the discussion